Copyright Reports & Markets. All rights reserved.

Global Imatinib Mesylate Tablets Market Growth (Status and Outlook) 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Imatinib Mesylate Tablets Market Size 2017-2028
    • 2.1.2 Imatinib Mesylate Tablets Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 Imatinib Mesylate Tablets Segment by Type
    • 2.2.1 100 mg
    • 2.2.2 400 mg
  • 2.3 Imatinib Mesylate Tablets Market Size by Type
    • 2.3.1 Imatinib Mesylate Tablets Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global Imatinib Mesylate Tablets Market Size Market Share by Type (2017-2022)
  • 2.4 Imatinib Mesylate Tablets Segment by Application
    • 2.4.1 Hospital
    • 2.4.2 Clinics
  • 2.5 Imatinib Mesylate Tablets Market Size by Application
    • 2.5.1 Imatinib Mesylate Tablets Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global Imatinib Mesylate Tablets Market Size Market Share by Application (2017-2022)

3 Imatinib Mesylate Tablets Market Size by Player

  • 3.1 Imatinib Mesylate Tablets Market Size Market Share by Players
    • 3.1.1 Global Imatinib Mesylate Tablets Revenue by Players (2020-2022)
    • 3.1.2 Global Imatinib Mesylate Tablets Revenue Market Share by Players (2020-2022)
  • 3.2 Global Imatinib Mesylate Tablets Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Imatinib Mesylate Tablets by Regions

  • 4.1 Imatinib Mesylate Tablets Market Size by Regions (2017-2022)
  • 4.2 Americas Imatinib Mesylate Tablets Market Size Growth (2017-2022)
  • 4.3 APAC Imatinib Mesylate Tablets Market Size Growth (2017-2022)
  • 4.4 Europe Imatinib Mesylate Tablets Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa Imatinib Mesylate Tablets Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas Imatinib Mesylate Tablets Market Size by Country (2017-2022)
  • 5.2 Americas Imatinib Mesylate Tablets Market Size by Type (2017-2022)
  • 5.3 Americas Imatinib Mesylate Tablets Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Imatinib Mesylate Tablets Market Size by Region (2017-2022)
  • 6.2 APAC Imatinib Mesylate Tablets Market Size by Type (2017-2022)
  • 6.3 APAC Imatinib Mesylate Tablets Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Imatinib Mesylate Tablets by Country (2017-2022)
  • 7.2 Europe Imatinib Mesylate Tablets Market Size by Type (2017-2022)
  • 7.3 Europe Imatinib Mesylate Tablets Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Imatinib Mesylate Tablets by Region (2017-2022)
  • 8.2 Middle East & Africa Imatinib Mesylate Tablets Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa Imatinib Mesylate Tablets Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Imatinib Mesylate Tablets Market Forecast

  • 10.1 Global Imatinib Mesylate Tablets Forecast by Regions (2023-2028)
    • 10.1.1 Global Imatinib Mesylate Tablets Forecast by Regions (2023-2028)
    • 10.1.2 Americas Imatinib Mesylate Tablets Forecast
    • 10.1.3 APAC Imatinib Mesylate Tablets Forecast
    • 10.1.4 Europe Imatinib Mesylate Tablets Forecast
    • 10.1.5 Middle East & Africa Imatinib Mesylate Tablets Forecast
  • 10.2 Americas Imatinib Mesylate Tablets Forecast by Country (2023-2028)
    • 10.2.1 United States Imatinib Mesylate Tablets Market Forecast
    • 10.2.2 Canada Imatinib Mesylate Tablets Market Forecast
    • 10.2.3 Mexico Imatinib Mesylate Tablets Market Forecast
    • 10.2.4 Brazil Imatinib Mesylate Tablets Market Forecast
  • 10.3 APAC Imatinib Mesylate Tablets Forecast by Region (2023-2028)
    • 10.3.1 China Imatinib Mesylate Tablets Market Forecast
    • 10.3.2 Japan Imatinib Mesylate Tablets Market Forecast
    • 10.3.3 Korea Imatinib Mesylate Tablets Market Forecast
    • 10.3.4 Southeast Asia Imatinib Mesylate Tablets Market Forecast
    • 10.3.5 India Imatinib Mesylate Tablets Market Forecast
    • 10.3.6 Australia Imatinib Mesylate Tablets Market Forecast
  • 10.4 Europe Imatinib Mesylate Tablets Forecast by Country (2023-2028)
    • 10.4.1 Germany Imatinib Mesylate Tablets Market Forecast
    • 10.4.2 France Imatinib Mesylate Tablets Market Forecast
    • 10.4.3 UK Imatinib Mesylate Tablets Market Forecast
    • 10.4.4 Italy Imatinib Mesylate Tablets Market Forecast
    • 10.4.5 Russia Imatinib Mesylate Tablets Market Forecast
  • 10.5 Middle East & Africa Imatinib Mesylate Tablets Forecast by Region (2023-2028)
    • 10.5.1 Egypt Imatinib Mesylate Tablets Market Forecast
    • 10.5.2 South Africa Imatinib Mesylate Tablets Market Forecast
    • 10.5.3 Israel Imatinib Mesylate Tablets Market Forecast
    • 10.5.4 Turkey Imatinib Mesylate Tablets Market Forecast
    • 10.5.5 GCC Countries Imatinib Mesylate Tablets Market Forecast
  • 10.6 Global Imatinib Mesylate Tablets Forecast by Type (2023-2028)
  • 10.7 Global Imatinib Mesylate Tablets Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Teva Pharmaceuticals
    • 11.1.1 Teva Pharmaceuticals Company Information
    • 11.1.2 Teva Pharmaceuticals Imatinib Mesylate Tablets Product Offered
    • 11.1.3 Teva Pharmaceuticals Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Teva Pharmaceuticals Main Business Overview
    • 11.1.5 Teva Pharmaceuticals Latest Developments
  • 11.2 Hikma Pharmaceuticals
    • 11.2.1 Hikma Pharmaceuticals Company Information
    • 11.2.2 Hikma Pharmaceuticals Imatinib Mesylate Tablets Product Offered
    • 11.2.3 Hikma Pharmaceuticals Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Hikma Pharmaceuticals Main Business Overview
    • 11.2.5 Hikma Pharmaceuticals Latest Developments
  • 11.3 Apotex Inc
    • 11.3.1 Apotex Inc Company Information
    • 11.3.2 Apotex Inc Imatinib Mesylate Tablets Product Offered
    • 11.3.3 Apotex Inc Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 Apotex Inc Main Business Overview
    • 11.3.5 Apotex Inc Latest Developments
  • 11.4 Sun Pharmaceutical Industries
    • 11.4.1 Sun Pharmaceutical Industries Company Information
    • 11.4.2 Sun Pharmaceutical Industries Imatinib Mesylate Tablets Product Offered
    • 11.4.3 Sun Pharmaceutical Industries Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 Sun Pharmaceutical Industries Main Business Overview
    • 11.4.5 Sun Pharmaceutical Industries Latest Developments
  • 11.5 Lupin Limited
    • 11.5.1 Lupin Limited Company Information
    • 11.5.2 Lupin Limited Imatinib Mesylate Tablets Product Offered
    • 11.5.3 Lupin Limited Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Lupin Limited Main Business Overview
    • 11.5.5 Lupin Limited Latest Developments
  • 11.6 Natco Pharma
    • 11.6.1 Natco Pharma Company Information
    • 11.6.2 Natco Pharma Imatinib Mesylate Tablets Product Offered
    • 11.6.3 Natco Pharma Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 Natco Pharma Main Business Overview
    • 11.6.5 Natco Pharma Latest Developments
  • 11.7 Getwell Oncology
    • 11.7.1 Getwell Oncology Company Information
    • 11.7.2 Getwell Oncology Imatinib Mesylate Tablets Product Offered
    • 11.7.3 Getwell Oncology Imatinib Mesylate Tablets Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 Getwell Oncology Main Business Overview
    • 11.7.5 Getwell Oncology Latest Developments

12 Research Findings and Conclusion

As the global economy mends, the 2021 growth of Imatinib Mesylate Tablets will have significant change from previous year. According to our (LP Information) latest study, the global Imatinib Mesylate Tablets market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Imatinib Mesylate Tablets market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.

The United States Imatinib Mesylate Tablets market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Imatinib Mesylate Tablets market, reaching US$ million by the year 2028. As for the Europe Imatinib Mesylate Tablets landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.

Global main Imatinib Mesylate Tablets players cover Teva Pharmaceuticals, Hikma Pharmaceuticals, Apotex Inc, and Sun Pharmaceutical Industries, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Imatinib Mesylate Tablets market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.

100 mg
400 mg

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.

Hospital
Clinics

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.

Teva Pharmaceuticals
Hikma Pharmaceuticals
Apotex Inc
Sun Pharmaceutical Industries
Lupin Limited
Natco Pharma
Getwell Oncology
Buy now